Synaptogenix

CannaSoul Analytics is a pioneer in the analysis of cannabis-based products, treatments, and pharmaceuticals, founded by Shmuel Mandel in 2018. The company specializes in the comprehensive analysis of over 100 cannabinoids and 100 terpenes, as well as offering unique endocannabinoid analysis across various matrices. CannaSoul is dedicated to advancing drug discovery through the development of botanical medicine and therapeutics derived from natural compounds. Its services include cannabis molecular analysis, intellectual property licensing, and clinical and pre-clinical trials. Additionally, CannaSoul engages in the screening of cannabis and psilocybin extracts, isolated cannabinoids, and novel molecules using various cell line models, thereby facilitating the integration of botanical medicine into the pharmaceutical industry.